Apnimed Inc.

Based in the US, Apnimed Inc. develops innovative therapeutic solutions for obstructive sleep apnea and related disorders, focusing on simplifying treatment to improve patient outcomes. Apnimed Inc. is dedicated to developing therapies for obstructive sleep apnea (OSA) and was founded in 2017 in Cambridge, US.

In March 2024, Shionogi Pharmaceutical acquired Apnimed Inc. from Tao Capital Partners, Columbia Seligman Investments, Morningside, Seligman Investments, Sectoral Asset Management, Alpha Wave Global, and NexPoint for USD 100 million. Founder Andrew Wellman has a history in the healthcare sector, contributing to Apnimed’s vision for transforming sleep medicine. Apnimed specializes in the development of innovative oral therapies for obstructive sleep apnea (OSA) and related sleep disorders.

Their core product, AD109, is an investigational oral therapy designed to simplify the treatment process for individuals suffering from OSA, particularly those who are untreated or undertreated. AD109 aims to address the underlying neuromuscular dysfunction associated with sleep-related breathing diseases, enhancing oxygenation and promoting restorative sleep. The company's products target a diverse customer base that includes healthcare providers, patients diagnosed with sleep apnea, and institutions focused on sleep health, primarily marketed within the United States and other regions where improved OSA treatments are needed. Apnimed’s revenue model is grounded in the commercialization of its novel therapies, particularly their flagship product, AD109, which is currently undergoing Phase 3 clinical trials.

Revenue generation will involve direct-to-consumer transactions as well as partnerships with healthcare providers and organizations specializing in sleep medicine. The company’s business structure may encompass licensing agreements or collaborations with pharmaceutical distributors to ensure broader access to their products. Pricing strategies could include subscription models for ongoing treatment options or one-time payments for initial prescriptions, though specific pricing details for AD109 and other potential products have not been publicly disclosed. The acquisition aims to accelerate progress by taking full control of the sleep disorder joint venture and its pipeline.